检索结果-南通市图书馆

基于机器学习和颅缝CT-MPR技术的北方成人年龄推断

在线全文

学校读者我要写书评

暂无评论

法医学杂志 2024年第2期40卷 128-134,142页

作者：魏璇陈雨珊丁杰宋长兴王俊静彭钊邓振华伊旭范飞四川大学华西基础医学与法医学院四川成都610041 秦皇岛市北戴河医院影像科河北秦皇岛066100 四川大学华西医院放射科四川成都610041

目的运用CT和多平面重组(multiplanar reformation,MPR)技术获取颅缝断层图像,建立中国北方汉族成人年龄推断模型,探讨颅缝闭合规律在中国北方汉族人群年龄推断中的适用性。方法回顾性收集29~80岁健康北方汉族成人头部CT样本132例。对... 详细信息

目的运用CT和多平面重组(multiplanar reformation,MPR)技术获取颅缝断层图像,建立中国北方汉族成人年龄推断模型,探讨颅缝闭合规律在中国北方汉族人群年龄推断中的适用性。方法回顾性收集29~80岁健康北方汉族成人头部CT样本132例。对颅骨进行容积重组(volume reconstruction,VR)和MPR,每例样本生成160张颅缝断层图像。根据颅缝闭合分级标准对颅缝MPR图像进行评分,分别计算矢状缝、左右侧冠状缝和左右侧人字缝的平均闭合等级。以上述等级为自变量,建立北方汉族成人年龄推断的线性回归模型和梯度提升回归、支持向量回归、决策树回归和贝叶斯岭回归4种机器学习模型,并评估各模型推断年龄的准确性。结果各颅缝闭合等级均与年龄呈正相关,其中矢状缝相关性最高。4种机器学习模型年龄推断的准确性均高于线性回归模型,其中支持向量回归模型的准确性最高,平均绝对误差为9.542岁。结论机器学习模型和颅骨CT-MPR技术可联合用于中国北方汉族成人的年龄推断,但在法医学实践中仍需与其他成人年龄推断指标联合使用。

关键词：法医人类学年龄推断机器学习颅缝计算机体层成像多平面重组汉族

Incidence and prognosis of olfactory and gustatory dysfunctions related to SARS-CoV-2 Omicron strain infection in China:A national multicenter survey of 35,566 individuals

在线全文

学校读者我要写书评

暂无评论

World Journal of Otorhinolaryngology-head and Neck Surgery 2024年第2期10卷 113-120页

作者： Meng-Fan Liu Rui-Xia Ma Xian-Bao Cao Hua Zhang shui-Hong Zhou Wei-Hong Jiang Yan Jiang jing-Wu Sun Qin-Tai Yang Xue-Zhong Li Ya-Nan Sun Li Shi Min Wang Xi-cheng song Fu-Quan chen Xiao-Shu Zhang Hong-Quan Wei Shao-Qing yu Dong-Dong Zhu Luo Ba Zhi-Wei Cao Xu-Ping Xiao Xin Wei Zhi-Hong Lin Feng-Hong chen Chun-Guang shan Guang-Ke Wang jing Ye Shen-Hong Qu chang-Qing Zhao Zhen-Lin Wang Hua-Bin Li Feng Liu Xiao-Bo Cui Sheng-Nan Ye Zheng Liu yu Xu Xiao Cai Wei Huang Ru-Xin Zhang yu-Lin Zhao Guo-Dong yu Guang-Gang Shi Mei-Ping Lu Yang Shen yu-Tong Zhao Jia-Hong Pei Shao-Bing Xie Long-Gang yu Ye-Hai Liu Shao-Wei Gu yu-cheng Yang Lei cheng Jian-Feng liu Graduate School of Beijing University of Chinese Medicine BeijingChina Department of Otorhinolaryngology head and Neck Surgery China-Japan Friendship HospitalBeijingChina Department of Otorhinolaryngology head and Neck Surgery The First People's Hospital of YinchuanYinchuanChina Department of Otorhinolaryngology The First People's Hospital of Yunnan ProvinceKunmingChina Department of Otorhinolaryngology The First Affiliated Hospital of Xinjiang Medical UniversityUrumqiChina Department of Otorhinolaryngology head and Neck Surgery The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina Department of Otorhinolaryngology head and Neck Surgery Xiangya Hospital Central South UniversityChangshaChina Department of Otorhinolaryngology head and Neck Surgery The Affiliated Hospital of Qingdao UniversityQingdaoChina Department of Otorhinolaryngology head and Neck Surgery The First Affiliated Hospital of USTCHefeiChina Department of Otorhinolaryngology head and Neck Surgery The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of Otorhinolaryngology head and Neck Surgery Qilu Hospital of Shandong UniversityJinanChina Department of Otorhinolaryngology head and Neck Surgery The Second Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Otolaryngology The Second Hospital of Shandong UniversityShandong UniversityJinanChina Department of Otorhinolaryngology head and Neck Surgery Peking University People's HospitalBeijingChina Department of Otorhinolaryngology head and Neck Surgery Yantai Yuhuangding HospitalQingdao UniversityYantaiChina Department of Otorhinolaryngology head and Neck Surgery Xijing HospitalThe Fourth Military Medical UniversityXi'anChina Gansu Provincial Center for Disease Control and Prevention LanzhouChina Department of Otorhinolaryngology head and Neck Surgery The First Affiliated Hospital of China Medical UniversityShenyangChina Department of Otorhinolaryngology head and Neck Surgery Tongji Hospit

Objective:This cross-sectional study aimed to determine the epidemiology of olfactory and gustatory dysfunctions related to COVID-19 in ***:This study was conducted by 45 tertiary Grade-A hospitals in *** and offline questionnaire data were obtained from patients infected with COVID-19 between December 28,2022,and February 21,*** collected information included basic demographics,medical history,smoking and drinking history,vaccination history,changes in olfactory and gustatory functions before and after infection,and other postinfection symptoms,as well as the duration and improvement status of olfactory and gustatory ***:Complete questionnaires were obtained from 35,566 *** overall incidence of olfactory and taste dysfunction was 67.75%.Being female or being a cigarette smoker increased the likelihood of developing olfactory and taste *** received four doses of the vaccine or having good oral health or being a alcohol drinker decreased the risk of such *** infection,the average olfactory and taste VAS scores were 8.41 and 8.51,respectively;after infection,they decreased to 3.69 and 4.29 and recovered to 5.83 and 6.55 by the time of the *** median duration of dysosmia and dysgeusia was 15 and 12 days,respectively,with 0.5%of patients having symptoms lasting for more than 28 *** overall self-reported improvement rate was 59.16%.Recovery was higher in males,never smokers,those who received two or three vaccine doses,and those that had never experienced dental health issues,or chronic accompanying ***:The incidence of dysosmia and dysgeusia following infection with the SARS-CoV-2 virus is high in *** and prognosis are influenced by several factors,including sex,SARS-CoV-2 vaccination,history of head-facial trauma,nasal and oral health status,smoking and drinking history,and the persistence of accompanying symptoms.

关键词： epidemiologic studies incidence olfactory disorders prognosis SARS-CoV-2 taste disorders

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun chang yue chang Zhe chang Xinyuan chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che Bin chen Danping chen Fuqing chen Fusan chen Gang chen Guoming chen Hua-Xing chen Huirun chen Jinhui chen Ji-yuan chen Kai chen Mali chen Mingjun chen Mingshui chen Ning chen shanhong chen shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen Xiang chen Xiaoyu chen Xin chen Xun chen Xurong chen Ye chen Ying chen yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng Huajie cheng shan cheng Tongguang cheng yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang yue-yi Deng Wei Li Ya-ni he Zhao-hui Ni Yong-li Zhan shan Lin Zhi-yong Guo Jun Zhu jing-ai Fang Xu-sheng Liu Li-hua Wang Rong Wang Nian-song Wang Xiao-hong cheng Li-qun he Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen Wen-hu Liu Hong-li Lin Meng Liang Lu Ma Ming chen Li-qun song Jian chen Qing Zhu chang-ying Xing yun Li Ji-ning Gao Rong-shan Li Ying Li Hao Zhang Ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang he Guang-yan Cai Xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Phe losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

南海北部珠江口与琼东南盆地构造-热模拟研究

在线全文

学校读者我要写书评

暂无评论

地球物理学报 2011年第12期54卷 3057-3069页

作者：宋洋赵长煜张功成宋海斌单竞男陈林中国科学院地质与地球物理研究所油气资源研究重点实验室北京100029 中国科学院研究生院北京100049 中国地质大学(北京)地球物理与信息技术学院北京100083 中海石油(中国)有限公司北京研究中心北京100027

珠江口盆地和琼东南盆地位于南海北部的大陆边缘,本文在此地区选取了13条典型剖面,进行了构造沉降史和热史的模拟,初步探讨了其新生代以来的构造-热演化历史.其研究结果表明:珠江口盆地存在两次热流升高过程,分别为始新世(56.5～32 Ma)... 详细信息

珠江口盆地和琼东南盆地位于南海北部的大陆边缘,本文在此地区选取了13条典型剖面,进行了构造沉降史和热史的模拟,初步探讨了其新生代以来的构造-热演化历史.其研究结果表明:珠江口盆地存在两次热流升高过程,分别为始新世(56.5～32 Ma)和渐新世(32～23.3 Ma).琼东南盆地存在三期加热和两期冷却过程,始新世盆地热流缓慢升高,渐新世西部地区热流持续升高,而东部地区热流升高持续至16 Ma,并在5.4 Ma以来存在一期快速沉降,由西向东加热事件逐渐变弱.南海北部陆缘存在多期次裂谷作用、热流升高的特征;"热沉降"阶段也非完全处于热衰减期,晚期也存在热流升高的加热事件,这些都有别于典型的被动大陆边缘盆地的热演化模式.

关键词：琼东南盆地,珠江口盆地,构造-热演化,应变速率,古热流

STCF conceptual design report (Volume 1): Physics & detector

在线全文

学校读者我要写书评

暂无评论

Frontiers of physics 2024年第1期19卷 1-154页

作者： M.Achasov X.C.Ai L.P.An R.Aliberti Q.An X.Z.Bai Y.Bai O.Bakina A.Barnyakov V.Blinov V.Bobrovnikov D.Bodrov A.Bogomyagkov A.Bondar I.Boyko Z.H.Bu F.M.Cai H.Cai J.J.Cao Q.H.Cao X.Cao Z.Cao Q.chang K.T.Chao D.Y.chen H.chen H.X.chen J.F.chen K.chen L.L.chen P.chen S.L.chen S.M.chen S.chen S.P.chen W.chen X.chen X.F.chen X.R.chen Y.chen Y.Q.chen H.Y.cheng J.cheng S.cheng T.G.cheng J.P.Dai L.Y.Dai X.C.Dai D.Dedovich A.Denig I.Denisenko J.M.Dias D.Z.Ding L.Y.Dong W.H.Dong V.Druzhinin D.S.Du Y.J.Du Z.G.Du L.M.Duan D.Epifanov Y.L.Fan S.S.Fang Z.J.Fang G.Fedotovich C.Q.Feng X.Feng Y.T.Feng J.L.Fu J.Gao Y.N.Gao P.S.Ge C.Q.Geng L.S.Geng A.Gilman L.Gong T.Gong B.Gou W.Gradl J.L.Gu A.Guevara L.C.Gui A.Q.Guo F.K.Guo J.C.Guo J.Guo Y.P.Guo Z.H.Guo A.Guskov K.L.Han L.Han M.Han X.Q.Hao J.B.he S.Q.he X.G.he Y.L.he Z.B.he Z.X.heng B.L.Hou T.J.Hou Y.R.Hou C.Y.Hu H.M.Hu K.Hu R.J.Hu W.H.Hu X.H.Hu Y.C.Hu J.Hua G.S.Huang J.S.Huang M.Huang Q.Y.Huang W.Q.Huang X.T.Huang X.J.Huang Y.B.Huang Y.S.Huang N.Hüsken V.Ivanov Q.P.Ji J.J.Jia S.Jia Z.K.Jia H.B.Jiang J.Jiang S.Z.Jiang J.B.Jiao Z.Jiao H.J.jing X.L.Kang X.S.Kang B.C.Ke M.Kenzie A.Khoukaz I.Koop E.Kravchenko A.Kuzmin Y.Lei E.Levichev C.H.Li C.Li D.Y.Li F.Li G.Li G.Li H.B.Li H.Li H.N.Li H.J.Li H.L.Li J.M.Li J.Li L.Li L.Li L.Y.Li N.Li P.R.Li R.H.Li S.Li T.Li W.J.Li X.Li X.H.Li X.Q.Li X.H.Li Y.Li Y.Y.Li Z.J.Li H.Liang J.H.Liang Y.T.Liang G.R.Liao L.Z.Liao Y.Liao C.X.Lin D.X.Lin X.S.Lin B.J.Liu C.W.Liu D.Liu F.Liu G.M.Liu H.B.Liu J.Liu J.J.Liu J.B.Liu K.Liu K.Y.Liu K.Liu L.Liu Q.Liu S.B.Liu T.Liu X.Liu Y.W.Liu Y.Liu Y.L.Liu Z.Q.Liu Z.Y.Liu Z.W.Liu I.Logashenko Y.Long C.G.Lu J.X.Lu N.Lu Q.F.Lü Y.Lu Y.Lu Z.Lu P.Lukin F.J.Luo T.Luo X.F.Luo Y.H.Luo H.J.Lyu X.R.Lyu J.P.Ma P.Ma Y.Ma Y.M.Ma F.Maas S.Malde D.Matvienko Z.X.Meng R.Mitchell A.Nefediev Y.Nefedov S.L.Olsen Q.Ouyang P.Pakhlov G.Pakhlova X.Pan Y.Pan E.Passemar Y.P.Pei H.P.Peng L.Peng X.Y.Peng X.J.Peng K.Peters S.Pivovarov E.Pyata B.B.Qi Y.Q.Qi W.B.Qian Y.Qian C.F.Qiao J.J.Qin J.J.Qin L.Q.Qin X.S.Qin T.L.Qiu J.Rademacker C.F.Redmer H.Y.Sang Anhui University Hefei 230039China Beihang University Beijing 100191China Budker Institute of Nuclear Physics Novosibirsk 630090Russia CAS Key Laboratory of Theoretical Physics Institute of Theoretical PhysicsChinese Academy of SciencesBeijing 100190China Cavendish Laboratory University of CambridgeJJ Thomson AveCambridge CB30HEUnited Kingdom Central China Normal University Wuhan 430079China Central South University Changsha 410083China China University of Geosciences Wuhan 430074China China University of Mining and Technology Xuzhou 221116China École Polytechnique Fédérale de Lausanne(EPFL) LausanneSwitzerland Fudan University Shanghai 200433China Goethe University Frankfurt D-60325 Frankfurt am MainGermany Guangxi Normal University Guilin 541004China Guangxi Uninversity Nanning 530004China Hangzhou Institute for Advanced Study UCASHangzhou 310024China hebei Normal University Shijiazhuang 050024China hebei University Baoding 071002China hefei University of Technology Hefei 230601China helmholtz Institute Mainz Staudinger Weg 18D-55099 MainzGermany henan Normal University Xinxiang 453007China henan University Kaifeng 475004China High Energy Physics Center Chung-Ang UniversitySeoul 06974Korea Higher School of Economy 11 Pokrovsky Bulvar Moscow 109028Russia Huangshan University Huangshan 245000China Hubei University of Automotive Technology Shiyan 442002China Hunan Normal University Changsha 410081China Hunan University of Science and Technology Xiangtan 411201China Hunan University Changsha 410082China Indiana University BloomingtonIndiana 47405USA Inner Mongolia University Hohhot 010021China Institute of Advanced Science Facilities Shenzhen 518107China Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China Institute of Modern Physics Chinese Academy of SciencesLanzhou 730000China Institute of Physics Academia SinicaTaipeiTaiwan 11529China Institute of Theoretical Physics Chinese Academy of SciencesBeijing 100190China Jilin University Changch

The superτ-charm facility(STCF)is an electron–positron collider proposed by the Chinese particle physics *** is designed to operate in a center-of-mass energy range from 2 to 7 GeV with a peak luminosity of 0.5×10^(35) cm^(–2)·s^(–1) or *** STCF will produce a data sample about a factor of 100 larger than that of the presentτ-charm factory—the BEPCII,providing a unique platform for exploring the asymmetry of matter-antimatter(charge-parity violation),in-depth studies of the internal structure of hadrons and the nature of non-perturbative strong interactions,as well as searching for exotic hadrons and physics beyond the Standard *** STCF project in China is under development with an extensive R&D *** document presents the physics opportunities at the STCF,describes conceptual designs of the STCF detector system,and discusses future plans for detector R&D and physics case studies.

关键词： electron–positron collider tau-charm region high luminosity STCF detector conceptual design

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan shan Xu-Yong Wei Rui Wang chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang he Lin-Sen Ye Yang Yang yu-Ting he Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong chen Zhi-shui chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang he Qiang Xia Shao-Hua song Zhi-Ren Fu Wei Qiu Guo-yue Lv Rui-Peng song Ji-Zhou Wang Zheng Wang Jian Zhou Gang chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun he Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents hepatocellular carcinoma Liver transplantation Conversion

Structural Basis for Ubiquitin Recognition by a Novel Domain from Human Phospholipase A2 Activating Protein

在线全文

学校读者我要写书评

暂无评论

生物物理学报 2009年第S1期25卷 326-326页

作者： Qing-shan Fu chen-Jie Zhou Hong-chang Gao Ya-Jun Jiang Zi-Ren Zhou jing Hong Wen-Ming Yao Ai-Xin song Dong-Hai Lin Hong-yu Hu State Key Laboratory of Molecular Biology Institute of Biochemistry and Cell BiologyShanghai Institutes for Biological SciencesChinese Academy of SciencesShanghai 200031China shanghai Institute of Materia Medica Shanghai Institutes for Biological SciencesChinese Academy of SciencesShanghai 201203China Graduate School of the Chinese Academy of Sciences 19A Yu Quan RoadBeijing 100039China

Ubiquitin (Ub) is an essential modifier conserved in all eukaryotes from yeast to human. Phospholipase A2 activating protein (PLAA), a mammalian homolog of yeast DOA1/UFD3.

关键词： ubiquitin ubiquitin-binding domain solution structure cis/trans isomerization PLAA.

Construction of a genetic linkage map and mapping of a female-specific DNA marker in half-smooth tongue sole（Cynoglossus semilaevis）

在线全文

学校读者我要写书评

暂无评论

Construction of a genetic linkage map and mapping of a femal...